To determine the safety and toxicity of intravenous docetaxel, administered on a weekly schedule (3 weeks out of 4), in combination with oral lonafarnib, administered on a daily schedule, in patients with locally advanced and metastatic solid tumor malignancies which are refractory to the standard of care.~To determine the pharmacokinetic interaction between docetaxel and lonafarnib.~To determine the molecular interaction in peripheral blood mononuclear cells between docetaxel and lonafarnib
To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.